Navigation Links
BioMarin to Present at the Baird Healthcare Conference
Date:9/2/2009

NOVATO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Senior Vice President and Chief Medical Officer of BioMarin, will present a company update at the Baird Healthcare Conference in New York City on Wednesday, September 9, 2009 at 3:45 p.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press r
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
10. BioMarin to Present at the Morgan Stanley Healthcare Conference
11. BioMarin Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week sponsored ... Longevity Research’ and welcomed a host of London-based ... Innovation Center for the event, organised by the ... The meeting highlighted the need for both philanthropic ... disease, as well as the crucial role of ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2
... DUBLIN, September 30, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... With MSD for Long-Term Commercial Supply of Microplasmin -- LEUVEN, Belgium, September 30, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
... Spring Harbor, NY -- The story of the double helix,s ... source -- a never-before-read stack of letters to and from ... 1950-76 -- has been uncovered by two professors at the ... (CSHL). The letters both confirm and extend ...
Cached Biology Technology:Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 2Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 3Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 4Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 5Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 6Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 7Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 8ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 2ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 3ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 4ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 5ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 6ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 7ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 8New twists in double helix discovery story are uncovered 2New twists in double helix discovery story are uncovered 3
(Date:7/11/2014)... hippocampus, the marginal division of the striatum is ... the impact degree of substance P in the ... Yan Yu and his team, College of Biophotonics, ... staining, that substance P receptor, neurokinin 1 was ... division of normal rats. Unilateral or bilateral injection ...
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... NEW YORK (Nov. 9, 2010) -- Weill Cornell ... $100,000 grants from the Bill & Melinda Gates Foundation ... Explorations, an initiative to encourage bold and unconventional ideas ... to promising and innovative global health research projects conducted ...
... Colo. (Nov. 9, 2010) As dog bites become an increasingly ... are most at risk for bites, that the culprits are usually ... with the second attack often more brutal than the first. ... Durairaj, MD, of the University of Colorado School of Medicine, who ...
... release is available in Spanish . , U.S. ... ways to improve soil on degraded land so it can ... with USDA,s Agricultural Research Service (ARS) at the agency,s Appalachian ... constructed or replacement subsoils and topsoils to build better and ...
Cached Biology News:Gates Foundation continues funding of tuberculosis research at Weill Cornell 2Gates Foundation continues funding of tuberculosis research at Weill Cornell 3Study shows young, unsupervised children most at risk for dog bites 2Improving soil for better lawns and gardens 2
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Validated and Silencer Pre-designed siRNAs, ...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
... HT, 1 kit. Facilitates the simple, phenol-free ... and hard tissue requiring proteinase K digestion.Each ... DNA from 50 preparations of up to ... Synthesis & Purification, Purification and Amplification of ...
Biology Products: